The ability to diagnose MI was better with troponin I, but T better predicted mortality. Both tests have strengths, ...

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.